EGFR and neoplasm: Studies based on clinical cases of MCGs have found that certain mutations, such as IDH1/2, TERTp, PTEN, and TP53, EGFR, CDKN2A in a less proportion, are more often to occur at early stages of tumor evolution (Figure 2) (9, 70, 71).